Compare Biogen Inc (BIIB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Novartis AG — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 9.8× Biogen Inc's market cap, and Novartis AG pays a 3.07% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NVS | |
|---|---|---|
Market Cap | $30.13B | $295.37B |
Sector | Health | Health |
52-Week High | $216.63 | $168.62 |
52-Week Low | $128.93 | $119.31 |
Enterprise Value | $37.20B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
